November 22nd 2024
Researchers found the TYK2 inhibitor deucravacitinib offers superior efficacy to apremilast and comparable outcomes to biologics.
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Dermalorian™ Webinar Series on Moderate to Severe Atopic Dermatitis
November 21, 2024 - December 5, 2024
View More
21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
February 8, 2025
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Can Psoriasis Be Managed With Diet and Supplements?
August 17th 2022Wilson Liao, MD, professor and vice chair of research in the Department of Dermatology at the University of California, San Francisco (UCSF) School of Medicine, and colleagues conducted a study examining the role of supplements and diets in managing psoriasis.
Key Pearls on Innovative Treatments in PsA
June 26th 2022Arthur Kavanaugh, MD, a professor of medicine and director of the Center for Innovative Therapy (CIT) at UC San Diego in California, gives his thoughts on the treatments for psoriatic arthritis, the comorbidities that have to be considered, and more.